Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer

F Pietrantonio, R Miceli, Lorenza Rimassa, S Lonardi, G. Aprile, Alessia Mennitto, Federica Marmorino, Silvia Bozzarelli, L. Antonuzzo, Emiliano Tamburini, F Morano, D. Rossini, F Battaglin, Marina Baretti, R Berenato, Vittoria Formica, S. Mosconi, F. Petrelli, M. Ghidini, F LoupakisD Spada, S. Cinieri, G Beretta, A Falcone, F de Braud, C. Cremolini

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.PATIENTS AND METHODS: Four hundred-eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets.RESULTS: Four variables were selected and included in the nomogram: PS (p
Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalAnnals of Oncology
Volume28
Issue number3
DOIs
Publication statusPublished - Nov 17 2016

Fingerprint

Nomograms
Colorectal Neoplasms
Life Expectancy
Calibration
Cost-Benefit Analysis
Logistic Models
Survival
Pharmaceutical Preparations
TAS 102
regorafenib
Therapeutics

Keywords

  • Journal Article

Cite this

Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer. / Pietrantonio, F; Miceli, R; Rimassa, Lorenza; Lonardi, S; Aprile, G.; Mennitto, Alessia; Marmorino, Federica; Bozzarelli, Silvia; Antonuzzo, L.; Tamburini, Emiliano; Morano, F; Rossini, D.; Battaglin, F; Baretti, Marina; Berenato, R; Formica, Vittoria; Mosconi, S.; Petrelli, F.; Ghidini, M.; Loupakis, F; Spada, D; Cinieri, S.; Beretta, G; Falcone, A; de Braud, F; Cremolini, C.

In: Annals of Oncology, Vol. 28, No. 3, 17.11.2016, p. 555-561.

Research output: Contribution to journalArticle

Pietrantonio, F, Miceli, R, Rimassa, L, Lonardi, S, Aprile, G, Mennitto, A, Marmorino, F, Bozzarelli, S, Antonuzzo, L, Tamburini, E, Morano, F, Rossini, D, Battaglin, F, Baretti, M, Berenato, R, Formica, V, Mosconi, S, Petrelli, F, Ghidini, M, Loupakis, F, Spada, D, Cinieri, S, Beretta, G, Falcone, A, de Braud, F & Cremolini, C 2016, 'Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer', Annals of Oncology, vol. 28, no. 3, pp. 555-561. https://doi.org/10.1093/annonc/mdw627
Pietrantonio, F ; Miceli, R ; Rimassa, Lorenza ; Lonardi, S ; Aprile, G. ; Mennitto, Alessia ; Marmorino, Federica ; Bozzarelli, Silvia ; Antonuzzo, L. ; Tamburini, Emiliano ; Morano, F ; Rossini, D. ; Battaglin, F ; Baretti, Marina ; Berenato, R ; Formica, Vittoria ; Mosconi, S. ; Petrelli, F. ; Ghidini, M. ; Loupakis, F ; Spada, D ; Cinieri, S. ; Beretta, G ; Falcone, A ; de Braud, F ; Cremolini, C. / Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer. In: Annals of Oncology. 2016 ; Vol. 28, No. 3. pp. 555-561.
@article{eeaebe4fcf2245adb245b7cafb892cd5,
title = "Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer",
abstract = "BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.PATIENTS AND METHODS: Four hundred-eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets.RESULTS: Four variables were selected and included in the nomogram: PS (p",
keywords = "Journal Article",
author = "F Pietrantonio and R Miceli and Lorenza Rimassa and S Lonardi and G. Aprile and Alessia Mennitto and Federica Marmorino and Silvia Bozzarelli and L. Antonuzzo and Emiliano Tamburini and F Morano and D. Rossini and F Battaglin and Marina Baretti and R Berenato and Vittoria Formica and S. Mosconi and F. Petrelli and M. Ghidini and F Loupakis and D Spada and S. Cinieri and G Beretta and A Falcone and {de Braud}, F and C. Cremolini",
note = "{\circledC} The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2016",
month = "11",
day = "17",
doi = "10.1093/annonc/mdw627",
language = "English",
volume = "28",
pages = "555--561",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer

AU - Pietrantonio, F

AU - Miceli, R

AU - Rimassa, Lorenza

AU - Lonardi, S

AU - Aprile, G.

AU - Mennitto, Alessia

AU - Marmorino, Federica

AU - Bozzarelli, Silvia

AU - Antonuzzo, L.

AU - Tamburini, Emiliano

AU - Morano, F

AU - Rossini, D.

AU - Battaglin, F

AU - Baretti, Marina

AU - Berenato, R

AU - Formica, Vittoria

AU - Mosconi, S.

AU - Petrelli, F.

AU - Ghidini, M.

AU - Loupakis, F

AU - Spada, D

AU - Cinieri, S.

AU - Beretta, G

AU - Falcone, A

AU - de Braud, F

AU - Cremolini, C.

N1 - © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2016/11/17

Y1 - 2016/11/17

N2 - BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.PATIENTS AND METHODS: Four hundred-eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets.RESULTS: Four variables were selected and included in the nomogram: PS (p

AB - BACKGROUND: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.PATIENTS AND METHODS: Four hundred-eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets.RESULTS: Four variables were selected and included in the nomogram: PS (p

KW - Journal Article

U2 - 10.1093/annonc/mdw627

DO - 10.1093/annonc/mdw627

M3 - Article

VL - 28

SP - 555

EP - 561

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -